secwatch / observer
8-K filed June 3, 2026, 9:00 AM ET ticker VBIO CIK 0001787740
other material confidence high sentiment neutral materiality 0.35

Valion Bio shareholders approve 2.58M share increase to 2021 equity plan; Dean Zikria re-elected

Valion Bio, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series B Non-Voting Convertible Preferred Stock and exercise of related warrants to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 333,682 152,377 135,011* 637,190
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Series C Preferred Stock and exercise of related warrants (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 332,353 153,606 135,111* 637,190
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Approval of sale and issuance of common stock pursuant to Common Stock Purchase Agreement with Tumim Stone Capital, LLC (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 333,345 153,008
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Approval of Plan Amendment to increase shares authorized under the 2021 Amended and Restated 2021 Equity Incentive Plan by 2,581,608 shares at the 2026-05-28 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 736,919 134,918 60,707 637,190
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Approval of issuance of shares of common stock upon conversion of Senior Secured Convertible Note and exercise of warrant to 3i, LP (Nasdaq Rule 5635(d)) at the 2026-05-28 meeting.

Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Votes For Votes Against Abstentions Broker Non-Votes 332,456 153,503 135,111* 637,190
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Ratification of Rosenberg Rich Baker Berman, P.A. as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Proposal No. 3: The Company’s stockholders ratified the selection of Rosenberg Rich Baker Berman, P.A.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Valion Bio, Inc. shareholders approved Election of one Class II director at the 2026-05-28 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-28
Exact text from the filing
Name of Director Votes For Withhold Broker Non-Votes Dean Zikria 873,001 59,543 637,190
View on SEC.gov

163 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Valion Bio, Inc. filing history →

Source: SEC EDGAR
accession 0001683168-26-004481
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.